ADVANCED/METASTATIC COLORECTAL CANCER  Inclusion Criteria:  signed and dated ICF prior to initiation of study-specific procedures histologically confirmed metastatic CRC who are planned for or who have received no more than one cycle of first-line treatment in the advanced/metastatic setting with a fluoropyrimidine and oxaliplatin in combination with bevacizumab measurable and unresectable disease according to RECIST v1.1 known KRAS status availability of FFPE tumor specimens from biopsy within the previous 12 months for sequencing and neoantigen prediction ≥ 12 years of age ECOG performance status of 0 or 1 or equivalent for patients of 12-17 years of age adequate organ function (further defined in protocol)  Exclusion Criteria:  known microsatellite instability (MSI)hi disease based on institutional standard known tumor mutation burden <1 nonsynonymous mutations/MB patients with BRAF V600E mutations  LOCALIZED COLON CANCER  Inclusion Criteria:  signed and dated ICF prior to initiation of study-specific procedures high-risk stage II or stage III colon cancer planned for or have completed surgical resection and have not initiated or received more than 4 weeks of adjuvant chemotherapy and be known ctDNA-positive via the Signatera assay availability of FFPE tumor specimens for sequencing, determination of mutations for detecting and monitoring ctDNA to identify patients with minimal residual disease, and neoantigen prediction ≥ 12 years of age ECOG performance status of 0 or 1 or equivalent for patients of 12-17 years of age adequate organ function (further defined in protocol)  Exclusion Criteria:  known microsatellite instability (MSI)hi disease based on institutional standard known tumor mutation burden <1 nonsynonymous mutations/MB  Complete list of inclusion and exclusion criteria are listed in the clinical study protocol